Switching to upadacitinib after treatment with a tumor necrosis factor inhibitor may benefit patients with psoriatic arthritis.

Treatment with TNFi was associated with increased adherence and drug survival when compared with IL-17i and JAKi in patients with ankylosing spondylitis.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-mo ...

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus ...

Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

A scientific statement has been published by the American College of Cardiology regarding inflammation and cardiovascular disease.

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear ...

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared ...

Biotech investing is often a high-risk, high-reward game, with clinical trial results capable of sending stocks soaring or plummeting. For investors willing to bet on scientific breakthroughs, these ...

Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...

Reliance Industries Chairman Mukesh Ambani topped the M3M Hurun India Rich List 2025, becoming Indian's richest person with a wealth of ₹9.55 lakh crore, despite a 6 percent year-on-year decline in ...